Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00419770 | The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study | PHASE2 | COMPLETED | 20 | — | — | Oct 1, 2007 | Dec 1, 2010 | Oct 16, 2023 | 7 | United States |
| Arm | Type | Description |
|---|---|---|
| B | EXPERIMENTAL | Deferasirox |
| A | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| deferasirox | DRUG | 20 mg/kg enterally per day |
| Placebo | DRUG | - |
| Liposomal amphotericin B | DRUG | - |
Inclusion Criteria: * Age greater than 2 years. * Proven or probable invasive mucormycosis, as defined by modification of consensus European Organization for Research and Treatment of Cancer (EORTC)/Mycosis Study Group (MSG) criteria. In brief, proven mucormycosis is defined as: 1) histopathologic ...